Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

NCT04952610 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT04952610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 13, 2021
Completion date
April 10, 2026
Enrollment
130 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia